![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCL4L2 |
Gene summary for CCL4L2 |
![]() |
Gene information | Species | Human | Gene symbol | CCL4L2 | Gene ID | 9560 |
Gene name | C-C motif chemokine ligand 4 like 2 | |
Gene Alias | AT744.2 | |
Cytomap | 17q12 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q8NHW4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9560 | CCL4L2 | C21 | Human | Oral cavity | OSCC | 1.05e-51 | 1.57e+00 | 0.2678 |
9560 | CCL4L2 | C30 | Human | Oral cavity | OSCC | 1.69e-49 | 1.72e+00 | 0.3055 |
9560 | CCL4L2 | C38 | Human | Oral cavity | OSCC | 1.16e-02 | 1.35e+00 | 0.172 |
9560 | CCL4L2 | C46 | Human | Oral cavity | OSCC | 5.19e-19 | 2.21e-01 | 0.1673 |
9560 | CCL4L2 | C51 | Human | Oral cavity | OSCC | 6.74e-04 | 1.60e-01 | 0.2674 |
9560 | CCL4L2 | C07 | Human | Oral cavity | OSCC | 1.88e-03 | 5.39e-01 | 0.2491 |
9560 | CCL4L2 | C09 | Human | Oral cavity | OSCC | 7.91e-12 | 1.27e-01 | 0.1431 |
9560 | CCL4L2 | LN22 | Human | Oral cavity | OSCC | 1.03e-04 | 5.12e-01 | 0.1733 |
9560 | CCL4L2 | LN46 | Human | Oral cavity | OSCC | 3.90e-08 | 2.89e-01 | 0.1666 |
9560 | CCL4L2 | SYSMH6 | Human | Oral cavity | OSCC | 6.61e-20 | 1.46e-01 | 0.1275 |
9560 | CCL4L2 | PTCwithHT_1 | Human | Thyroid | HT | 2.77e-26 | 1.51e+00 | 0.0238 |
9560 | CCL4L2 | PTCwithHT_6 | Human | Thyroid | HT | 1.78e-21 | 9.11e-01 | 0.02 |
9560 | CCL4L2 | PTCwithHT_8 | Human | Thyroid | HT | 6.49e-27 | 1.12e+00 | 0.0351 |
9560 | CCL4L2 | PTCwithoutHT_2 | Human | Thyroid | PTC | 5.62e-15 | 8.26e-01 | 0.0419 |
9560 | CCL4L2 | PTCwithoutHT_7 | Human | Thyroid | PTC | 3.58e-09 | 9.64e-01 | 0.0381 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Liver | Cyst | ![]() |
Lung | IAC | ![]() |
Lung | AIS | ![]() |
Lung | AAH | ![]() |
Lung | MIAC | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516328 | Oral cavity | OSCC | Human cytomegalovirus infection | 139/3704 | 225/8465 | 2.77e-08 | 2.38e-07 | 1.21e-07 | 139 |
hsa040644 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa04623 | Oral cavity | OSCC | Cytosolic DNA-sensing pathway | 44/3704 | 75/8465 | 6.44e-03 | 1.51e-02 | 7.68e-03 | 44 |
hsa04620 | Oral cavity | OSCC | Toll-like receptor signaling pathway | 58/3704 | 104/8465 | 8.77e-03 | 1.98e-02 | 1.01e-02 | 58 |
hsa05163112 | Oral cavity | OSCC | Human cytomegalovirus infection | 139/3704 | 225/8465 | 2.77e-08 | 2.38e-07 | 1.21e-07 | 139 |
hsa0406411 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa046231 | Oral cavity | OSCC | Cytosolic DNA-sensing pathway | 44/3704 | 75/8465 | 6.44e-03 | 1.51e-02 | 7.68e-03 | 44 |
hsa046201 | Oral cavity | OSCC | Toll-like receptor signaling pathway | 58/3704 | 104/8465 | 8.77e-03 | 1.98e-02 | 1.01e-02 | 58 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCL4L2 | SNV | Missense_Mutation | novel | c.148G>A | p.Asp50Asn | p.D50N | Q8NHW4 | protein_coding | deleterious(0.02) | possibly_damaging(0.685) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
CCL4L2 | SNV | Missense_Mutation | novel | c.13G>A | p.Val5Met | p.V5M | Q8NHW4 | protein_coding | tolerated(0.05) | benign(0.007) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
CCL4L2 | SNV | Missense_Mutation | novel | c.5N>C | p.Lys2Thr | p.K2T | Q8NHW4 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCL4L2 | SNV | Missense_Mutation | novel | c.7N>T | p.Leu3Phe | p.L3F | Q8NHW4 | protein_coding | tolerated(0.11) | benign(0) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCL4L2 | SNV | Missense_Mutation | novel | c.80G>A | p.Gly27Asp | p.G27D | Q8NHW4 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CCL4L2 | SNV | Missense_Mutation | novel | c.274N>A | p.Val92Ile | p.V92I | Q8NHW4 | protein_coding | tolerated_low_confidence(0.34) | unknown(0) | TCGA-44-6777-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCL4L2 | SNV | Missense_Mutation | novel | c.260N>A | p.Pro87His | p.P87H | Q8NHW4 | protein_coding | tolerated_low_confidence(0.06) | benign(0.003) | TCGA-44-8117-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CCL4L2 | SNV | Missense_Mutation | novel | c.46N>T | p.Ala16Ser | p.A16S | Q8NHW4 | protein_coding | deleterious(0.05) | probably_damaging(0.931) | TCGA-34-8455-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
CCL4L2 | SNV | Missense_Mutation | novel | c.306N>T | p.Lys102Asn | p.K102N | Q8NHW4 | protein_coding | unknown(0) | TCGA-CV-7421-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CCL4L2 | SNV | Missense_Mutation | novel | c.253N>T | p.Ser85Cys | p.S85C | Q8NHW4 | protein_coding | deleterious(0.05) | benign(0.048) | TCGA-QK-A8Z7-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | carboplatin | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |